Surgery Godfather-Chapter 1872 - 1301: Professor, I’ve Discovered Another Secret

Dr. Carlos in Brazil did not give up, and after the first patient abandoned treatment due to distrust, he contacted local medical associations and patient organizations to hold a small K Therapy educational session. Most of the attendees were late-stage patients and their families, their eyes revealing similar despair and longing.

Carlos did not conceal any information: effectiveness, side effects, economic burden, technical uncertainties. He showed the Sanbo training class operation videos and international case data, and also openly discussed the limitations of adenovirus antibody screening and current solutions.

"Doctor, we’ve understood what you’ve said," a middle-aged man consulting for his wife said, "but how do we know this isn’t another scam? We’ve seen too many miracle therapies that end up being money pits."

Indeed, many fraudsters prey on terminal patients’ instinct to survive, promoting various miraculous treatments to deceive them, making it hard for patients to distinguish truth from falsehood.

"The inventor of K Therapy, Professor Yang Ping, is a Nobel Prize winner..." Carlos tried to explain. 𝕗𝕣𝐞𝐞𝘄𝐞𝚋𝚗𝗼𝘃𝗲𝗹.𝚌𝕠𝚖

But the patient’s family member said, "Many miracle treatments claim some Nobel affiliation or other prestigious background, we’re really struggling to tell the real from the fake."

Carlos paused, unsure how to respond.

Trust is something hard to build, and many issues are no longer medical problems but social issues.

That day, Carlos received only one treatment application. The patient was wealthy and didn’t care about money, just wanted to try, as there were no other options, even if it was a scam.

...

Shen Guohua began his second treatment: double-target A/B vector intravenous infusion, simultaneously initiating meticulously regulated immune modulator infusion.

On the first night post-treatment, Shen Guohua’s temperature rose to 38.5℃, heart rate accelerated, but blood pressure and blood oxygen saturation remained stable - a predictable immune activation response, within a controllable range.

At 3 a.m., Song Zimo, constantly monitoring various test data, suddenly noticed: "Interleukin-6 and Interferon-gamma are rapidly increasing, but tumor necrosis factor-alpha remains stable. This pattern is different from previous standalone vector treatments!"

This is a good sign, indicating the immune modulators are working, activating a smarter immune response pathway rather than a blind inflammatory storm.

The next morning, Shen Guohua experienced significantly worsened abdominal pain, but unlike previous cancer pain, it was a dull pain with a sense of bloating. Ultrasound showed significant liquefaction necrosis in the pancreatic tumor area, while the liver metastasis margins became blurred.

"The tumor is dissolving!" Doctor Li Chao’s voice was filled with excitement.

But bad news soon followed, at noon, Shen Guohua’s bilirubin began to slowly rise again, and coagulation function indicators showed slight abnormalities.

"The tumor’s dissolution might have released a large amount of intracellular substances, increasing the liver’s metabolic burden," Professor Yang Ping judged, "we need to strengthen support."

Support plan adjusted once more: on one hand the tumor retreats, on the other the body bears the cost of retreat, with weights constantly added and removed on both ends of the scale.

Another forty-eight hours later.

Shen Guohua’s bilirubin, after rising to a certain plateau, started to slowly but steadily decline, coagulation function returned to normal, abdominal pain reduced, tumor marker CA19-9 decreased to 5200U/mL.

Most encouragingly, the latest single-cell sequencing showed those sneaky tumor cells with high expression of rare receptors entering a dormant state, under the changes in immune microenvironment and metabolic pressure, some started becoming active again, and new "clues" emerged on their surfaces, the stress proteins they generated while adjusting to the new environment recognized by some activated immunocytes.

"Ground forces have discovered hidden enemy strongholds, though not completely eradicated, at least they can’t hide anymore, this battle can be fought," Professor Yang Ping said confidently, having a vague intuition of something more but unable to express just yet.

Shen Guohua’s vital signs gradually stabilized, transferring from ICU to a regular ward’s high-risk bed. He remained weak but could drink some water and speak a few words.

"Professor Yang..." his voice was faint.

Yang Ping leaned in closer.

"Thank you... for not giving up." Every word was laborious.

"You didn’t give up." Yang Ping held his hand, "Rest well, the battle isn’t over yet, but we’ve passed the toughest obstacle with you, next comes the long fight."

Shen Guohua’s lips moved slightly, as if into a smile, then he fell into a deep sleep.

Three days later, Shen Guohua was transferred from the high-risk ward to a regular single room, symbolizing stabilization of his condition.

But medically, stabilization is relative, Shen Guohua’s pancreatic primary lesion shrunk by 40%, liver metastasis partially liquefied necrosis, CA19-9 dropped to 3200U/mL. This merits a case report in a top-tier medical journal.

However, there were still quite a few residual tumor cells within him, they no longer highly expressed any known common receptors, but started secreting minor factors that disrupted local nerves and neovascularization, causing Shen Guohua intermittent inexplicable hidden pain and fatigue.

"Like guerrillas retreating underground, not engaging directly but constantly causing havoc, consuming your resources and willpower," Yang Ping analyzed, "our mission shifts from a blitz to a security operation, requiring long-term, low-intensity, multi-target maintenance strategy."

Maintenance plan quickly formulated: monthly low-dose double-target vector infusion, oral administration of two drugs regulating tumor microenvironment and metabolism, combined with strict nutritional support and moderate rehabilitation exercise. Additionally, weekly comprehensive blood and imaging monitoring to track tumor cell evolution in real-time.